International Journal of Molecular Medical Science, 2024, Vol.14, No.2, 144-152 http://medscipublisher.com/index.php/ijmms 150 Conflict of Interest Disclosure The authors affirm that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Aathira R., and Jain V., 2014, Advances in management of type 1 diabetes mellitus, World Journal of Diabetes, 5(5): 689. https://doi.org/10.4239/wjd.v5.i5.689 PMid:25317246 PMCid:PMC4138592 Beck R.W., Bergenstal R.M., Laffel L.M., and Pickup J.C., 2019, Advances in technology for management of type 1 diabetes, The Lancet, 394(10205): 1265-1273. https://doi.org/10.1016/S0140-6736(19)31142-0 PMid:31533908 Benhamou P.Y., Franc S., Reznik Y., Thivolet C., Schaepelynck P., Renard E., Guerci B., Chaillous L., Lukas-Croisier C., Jeandidier N., Hanaire H., Borot S., Doron M., Jallon P., Xhaard I., Melki V., Meyer L., Delemer B., Guillouche M., Schoumacker-Ley L., Farret A., Raccah D., Lablanche S., Joubert M., Penfornis A., and Charpentier G., 2019, Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial, The Lancet Digital Health, 1(1): e17-e25. https://doi.org/10.1016/S2589-7500(19)30003-2 PMid:33323237 Brown S.A., Forlenza G.P., Bode B.W., Pinsker J.E., Levy C.J., Criego A.B., Hansen D., Hirsch I., Carlson A., Bergenstal R., Sherr J., Mehta S., Laffel L., Shah V., Bhargava A., Weinstock R., Macleish S., DeSalvo D., Jones T., Aleppo G., Buckingham B., and Ly T.T., 2021, Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes, Diabetes Care, 44(7): 1630-1640. https://doi.org/10.2337/dc21-0172 PMid:34099518 PMCid:PMC8323171 Brusko T.M., Russ H.A., and Stabler C.L., 2021, Strategies for durable β cell replacement in type 1 diabetes, Science, 373(6554): 516-522. https://doi.org/10.1126/science.abh1657 PMid:34326233 PMCid:PMC8867839 Burnside M.J., Lewis D.M., Crocket H.R., Meier R.A., Williman J.A., Sanders O.J., Paul R., Lever C., Price S., Frewen C., Jones S., Gunn T., Lampey C., Wheeler B., and de Bock M.I., 2023, Extended use of an open-source automated insulin delivery system in children and adults with type 1 diabetes: the 24-week continuation phase following the CREATE randomized controlled trial, Diabetes Technology and Therapeutics, 25(4): 250-259. https://doi.org/10.1089/dia.2022.0484 PMid:36763345 Cahn A., Miccoli R., Dardano A., and Del Prato S., 2015, New forms of insulin and insulin therapies for the treatment of type 2 diabetes, The Lancet Diabetes and Endocrinology, 3(8): 638-652. https://doi.org/10.1016/S2213-8587(15)00097-2 PMid:26051044 Cahn A., Roitman E., Aharon-Hananel G., and Raz I., 2017, Continuous subcutaneous insulin infusion-an opportunity for better care but not a "magic pill", Endocrine, 56: 4-6. https://doi.org/10.1007/s12020-016-1217-x PMid:28039560 Cogger K., and Nostro M.C., 2015, Recent advances in cell replacement therapies for the treatment of type 1 diabetes, Endocrinology, 156(1): 8-15. https://doi.org/10.1210/en.2014-1691 PMid:25386833 Collyns O.J., Meier R.A., Betts Z.L., Chan D.S., Frampton C., Frewen C.M., Hewapathirana N., Jones S., Roy A., Grosman B., Kurtz N., Shin J., Vigersky R., Wheeler B., and de Bock M.I., 2021, Improved glycemic outcomes with medtronic minimed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes, Diabetes Care, 44(4): 969-975. https://doi.org/10.2337/dc20-2250 PMid:33579715 Couri C.E., Malmegrim K.C., and Oliveira M.C., 2018, New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement, Frontiers in Immunology, 9: 1086. https://doi.org/10.3389/fimmu.2018.01086 PMid:29868031 PMCid:PMC5968392 Dadlani V., Pinsker J.E., Dassau E., and Kudva Y.C., 2018, Advances in closed-loop insulin delivery systems in patients with type 1 diabetes, Current Diabetes Reports, 18: 1-10. https://doi.org/10.1007/s11892-018-1051-z PMid:30159816
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==